AllCells’ GMP Mobilized leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate mobilization of CD34+ hematopoietic stem and progenitor cells from the bone marrow to the peripheral blood. This procedure results in large-scale yields of CD34+ cells. Peripheral blood is collected from IRB-consented donors using the continuous flow Spectra Optia® Apheresis System directly into ACD-A anticoagulant at AllCells’ FDA-registered, IRB-approved collection facilities.
Regimen details: Reg H = Filgrastim (Neupogen®) 10ug/kg/day x 5 days + Plerixafor (Mozobil®) 240ug/kg/day x 2 days on day 4 and 5 (evenings), apheresis on day 5 and 6.
Donors with the right attributes are a critical part of any cell therapy program. AllCells Donor Management Services can help you find, screen and retain donors from our repository comprised of highly-characterized, HLA-typed donors with diverse demographics and clinical parameters that can meet program-specific criteria from research and development to commercialization.Learn More
GMP Mobilized Leukopak Products are enriched in CD34+, allowing for scalability and reproducibility. The product is quality controlled for viability using a validated AO/PI protocol and pass a Sterility Test in accordance with USP71 guidelines using compendial testing.
At AllCells, we believe that your success is our success. We believe that sharing our knowledge and expertise is more than a business practice, it’s a responsibility. And we believe that collaboration leads to better outcomes. Below is a collection of relevant links to Leukopak resouces including blog posts, webinars and useful protocols to help you become more efficient and more effective. Have technical questions about Leukopak products? Our Customer Success Team is standing by.
AllCells and Discovery Life Sciences advance science in an innovative, collaborative, and client-centric environment. We are grounded in a “Science at your Service” attitude.